ME Therapeutics Holdings Cash Flow Statement

Financials in millions CAD. Fiscal year is September - August.

Millions CAD. Fiscal year is Sep - Aug.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	2020
Period Ending	Aug '25 Aug 31, 2025	Aug '24 Aug 31, 2024	Aug '23 Aug 31, 2023	Aug '22 Aug 31, 2022	Aug '21 Aug 31, 2021	2020
Net Income	-1.19	-1.29	-6.52	-0.15	-0.07	Upgrade
Depreciation & Amortization	0.08	0	0	0	0	Upgrade
Stock-Based Compensation	0.17	0.7	0.62	0.01	0.03	Upgrade
Other Operating Activities	0.01	-	5.55	0.01	-	Upgrade
Change in Accounts Payable	0.11	-0.06	0.06	-0	0.02	Upgrade
Change in Other Net Operating Assets	-0.04	-0	-0.02	-0.01	0.02	Upgrade
Operating Cash Flow	-0.86	-0.66	-0.3	-0.14	0	Upgrade
Capital Expenditures	-0.22	-	-	-	-	Upgrade
Cash Acquisitions	-	-	0.76	-	-	Upgrade
Investment in Securities	-0.06	-	-	-	-	Upgrade
Other Investing Activities	-0.01	-	-	-	-	Upgrade
Investing Cash Flow	-0.28	-	0.76	-	-	Upgrade
Short-Term Debt Issued	-	-	-	0.14	-	Upgrade
Long-Term Debt Issued	-	-	-	-	0.02	Upgrade
Total Debt Issued	-	-	-	0.14	0.02	Upgrade
Short-Term Debt Repaid	-	-0.04	-	-	-	Upgrade
Long-Term Debt Repaid	-0.05	-	-	-	-	Upgrade
Total Debt Repaid	-0.05	-0.04	-	-	-	Upgrade
Net Debt Issued (Repaid)	-0.05	-0.04	-	0.14	0.02	Upgrade
Issuance of Common Stock	1.05	1.56	0.12	-	-	Upgrade
Other Financing Activities	-	-0.01	-	-	-	Upgrade
Financing Cash Flow	1	1.51	0.12	0.14	0.02	Upgrade
Net Cash Flow	-0.15	0.85	0.57	0	0.02	Upgrade
Free Cash Flow	-1.08	-0.66	-0.3	-0.14	0	Upgrade
Free Cash Flow Per Share	-0.04	-0.03	-0.02	-0.02	0.00	Upgrade
Levered Free Cash Flow	-0.7	-0.22	0.07	-0.1	0.03	Upgrade
Unlevered Free Cash Flow	-0.7	-0.22	0.08	-0.1	0.03	Upgrade
Change in Working Capital	0.06	-0.06	0.04	-0.01	0.05	Upgrade

Updated Aug 31, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.